XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 16 - Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Notes Tables |
Schedule of Segment Reporting Information, by Segment [Table Text Block] |
|  | During the Three-Month |
|  | Period Ended September 30, 2025 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 5,444,619 |  |  | $ | 61,503 |  |  | $ | — |  |  | $ | 5,506,122 |
Costs of goods sold |  |  | 3,100,872 |  |  |  | 42,152 |  |  |  | — |  |  |  | 3,143,024 |
Gross margin |  |  | 2,343,747 |  |  |  | 19,351 |  |  |  | — |  |  |  | 2,363,098 |
Sales and marketing expenses |  |  | 837,141 |  |  |  | 82,150 |  |  |  | — |  |  |  | 919,291 |
Product development expenses |  |  | 88,894 |  |  |  | 575,642 |  |  |  | 29,775 |  |  |  | 694,311 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 729,421 |  |  |  | 729,421 |
Operating expenses |  |  | 926,035 |  |  |  | 657,792 |  |  |  | 759,196 |  |  |  | 2,343,023 |
NET OPERATING INCOME (LOSS) |  | $ | 1,417,712 |  |  | $ | (638,441 | ) |  | $ | (759,196 | ) |  | $ | 20,075 |
|  | During the Three-Month |
|  | Period Ended September 30, 2024 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 5,951,344 |  |  | $ | 60,229 |  |  | $ | — |  |  | $ | 6,011,573 |
Costs of goods sold |  |  | 4,364,950 |  |  |  | 63,069 |  |  |  | — |  |  |  | 4,428,019 |
Gross margin |  |  | 1,586,394 |  |  |  | (2,840 | ) |  |  | — |  |  |  | 1,583,554 |
Sales and marketing expenses |  |  | 699,584 |  |  |  | 144,461 |  |  |  | — |  |  |  | 844,045 |
Product development expenses |  |  | 59,140 |  |  |  | 690,052 |  |  |  | 36,944 |  |  |  | 786,136 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 528,267 |  |  |  | 528,267 |
Operating expenses |  |  | 758,724 |  |  |  | 834,513 |  |  |  | 565,211 |  |  |  | 2,158,448 |
NET OPERATING INCOME (LOSS) |  | $ | 827,670 |  |  | $ | (837,353 | ) |  | $ | (565,211 | ) |  | $ | (574,894 | )
|  | During the Nine-Month |
|  | Period Ended September 30, 2025 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 19,871,621 |  |  | $ | 146,554 |  |  | $ | — |  |  | $ | 20,018,175 |
Costs of goods sold |  |  | 11,365,307 |  |  |  | 117,874 |  |  |  | — |  |  |  | 11,483,181 |
Gross margin |  |  | 8,506,314 |  |  |  | 28,680 |  |  |  | — |  |  |  | 8,534,994 |
Sales and marketing expenses |  |  | 2,259,124 |  |  |  | 212,911 |  |  |  | — |  |  |  | 2,472,035 |
Product development expenses |  |  | 275,390 |  |  |  | 1,915,299 |  |  |  | 92,327 |  |  |  | 2,283,016 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 2,072,682 |  |  |  | 2,072,682 |
Operating expenses |  |  | 2,534,514 |  |  |  | 2,128,210 |  |  |  | 2,165,009 |  |  |  | 6,827,733 |
NET OPERATING INCOME (LOSS) |  | $ | 5,971,800 |  |  | $ | (2,099,530 | ) |  | $ | (2,165,009 | ) |  | $ | 1,707,261 |
|  | During the Nine-Month |
|  | Period Ended September 30, 2024 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 18,602,054 |  |  | $ | 139,986 |  |  | $ | — |  |  | $ | 18,742,040 |
Costs of goods sold |  |  | 13,487,348 |  |  |  | 145,294 |  |  |  | — |  |  |  | 13,632,642 |
Gross margin |  |  | 5,114,706 |  |  |  | (5,308 | ) |  |  | — |  |  |  | 5,109,398 |
Sales and marketing expenses |  |  | 2,224,836 |  |  |  | 405,089 |  |  |  | — |  |  |  | 2,629,925 |
Product development expenses |  |  | 154,233 |  |  |  | 2,821,525 |  |  |  | 103,431 |  |  |  | 3,079,189 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 1,661,838 |  |  |  | 1,661,838 |
Operating expenses |  |  | 2,379,069 |  |  |  | 3,226,614 |  |  |  | 1,765,269 |  |  |  | 7,370,952 |
NET OPERATING INCOME (LOSS) |  | $ | 2,735,637 |  |  | $ | (3,231,922 | ) |  | $ | (1,765,269 | ) |  | $ | (2,261,554 | )
|  | During the Year Ended |
|  | December 31, 2024 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 26,314,251 |  |  | $ | 178,918 |  |  | $ | — |  |  | $ | 26,493,169 |
Costs of goods sold |  |  | 18,382,949 |  |  |  | 169,176 |  |  |  | — |  |  |  | 18,552,125 |
Gross margin |  |  | 7,931,302 |  |  |  | 9,742 |  |  |  | — |  |  |  | 7,941,044 |
Product development expenses |  |  | 243,578 |  |  |  | 3,493,298 |  |  |  | 161,706 |  |  |  | 3,898,582 |
Sales and marketing expenses |  |  | 2,909,799 |  |  |  | 556,273 |  |  |  | — |  |  |  | 3,466,072 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 2,216,549 |  |  |  | 2,216,549 |
Operating expenses |  |  | 3,153,377 |  |  |  | 4,049,571 |  |  |  | 2,378,255 |  |  |  | 9,581,203 |
NET OPERATING INCOME (LOSS) |  | $ | 4,777,925 |  |  | $ | (4,039,829 | ) |  | $ | (2,378,255 | ) |  | $ | (1,640,159 | )
|  | During the Year Ended |
|  | December 31, 2023 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Product sales |  | $ | 17,293,933 |  |  | $ | 177,736 |  |  | $ | — |  |  | $ | 17,471,669 |
Costs of goods sold |  |  | 13,453,514 |  |  |  | 148,871 |  |  |  | — |  |  |  | 13,602,385 |
Gross margin |  |  | 3,840,419 |  |  |  | 28,865 |  |  |  | — |  |  |  | 3,869,284 |
Product development expenses |  |  | 11,103 |  |  |  | 4,242,329 |  |  |  | 141,420 |  |  |  | 4,394,852 |
Sales and marketing expenses |  |  | 2,447,137 |  |  |  | 641,078 |  |  |  | — |  |  |  | 3,088,215 |
Administrative expenses |  |  | — |  |  |  | — |  |  |  | 2,134,295 |  |  |  | 2,134,295 |
Operating expenses |  |  | 2,458,240 |  |  |  | 4,883,407 |  |  |  | 2,275,715 |  |  |  | 9,617,362 |
NET OPERATING INCOME (LOSS) |  | $ | 1,382,179 |  |  | $ | (4,854,542 | ) |  | $ | (2,275,715 | ) |  | $ | (5,748,078 | )
Total Assets, Depreciation and Amortization, and Capital Expenditures [Table Text Block] |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Total Assets as of September 30, 2025 |  | $ | 26,039,474 |  |  | $ | 15,610,993 |  |  | $ | 4,079,656 |  |  | $ | 45,730,123 |
Total Assets as of September 30, 2024 |  | $ | 23,672,583 |  |  | $ | 16,798,955 |  |  | $ | 3,977,335 |  |  | $ | 44,448,873 |
Depreciation and amortization expense during the three-month period ended September 30, 2025 |  | $ | 377,484 |  |  | $ | 313,719 |  |  | $ | 17,464 |  |  | $ | 708,667 |
Depreciation and amortization expense during the three-month period ended September 30, 2024 |  | $ | 346,430 |  |  | $ | 319,815 |  |  | $ | 19,682 |  |  | $ | 685,927 |
Capital Expenditures during the three-month period ended September 30, 2025 |  | $ | 582,304 |  |  | $ | 11,020 |  |  | $ | 600 |  |  | $ | 593,924 |
Capital Expenditures during the three-month period ended September 30, 2024 |  | $ | 87,286 |  |  | $ | 1,126 |  |  | $ | — |  |  | $ | 88,412 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Total Assets as of September 30, 2025 |  | $ | 26,039,474 |  |  | $ | 15,610,993 |  |  | $ | 4,079,656 |  |  | $ | 45,730,123 |
Total Assets as of September 30, 2024 |  | $ | 23,672,583 |  |  | $ | 16,798,955 |  |  | $ | 3,977,335 |  |  | $ | 44,448,873 |
Depreciation and amortization expense during the nine-month period ended September 30, 2025 |  | $ | 1,075,518 |  |  | $ | 942,553 |  |  | $ | 56,406 |  |  | $ | 2,074,477 |
Depreciation and amortization expense during the nine-month period ended September 30, 2024 |  | $ | 1,027,711 |  |  | $ | 958,260 |  |  | $ | 59,221 |  |  | $ | 2,045,192 |
Capital Expenditures during the nine-month period ended September 30, 2025 |  | $ | 1,056,490 |  |  | $ | 18,772 |  |  | $ | 2,871 |  |  | $ | 1,078,133 |
Capital Expenditures during the nine-month period ended September 30, 2024 |  | $ | 220,098 |  |  | $ | 49,411 |  |  | $ | — |  |  | $ | 269,509 |
|  | Scours |  |  | Mastitis |  |  | Other |  |  | Total |
Total Assets as of December 31, 2024 |  | $ | 24,644,294 |  |  | $ | 16,523,048 |  |  | $ | 3,933,135 |  |  | $ | 45,100,477 |
Total Assets as of December 31, 2023 |  | $ | 24,735,413 |  |  | $ | 17,827,839 |  |  | $ | 1,244,850 |  |  | $ | 43,808,102 |
Depreciation and amortization expense during the year ended December 31, 2024 |  | $ | 1,373,815 |  |  | $ | 1,277,218 |  |  | $ | 78,814 |  |  | $ | 2,729,847 |
Depreciation and amortization expense during the year ended December 31, 2023 |  | $ | 1,365,988 |  |  | $ | 1,287,600 |  |  | $ | 86,032 |  |  | $ | 2,739,620 |
Capital Expenditures during the year ended December 31, 2024 |  | $ | 409,696 |  |  | $ | 53,721 |  |  | $ | 2,308 |  |  | $ | 465,725 |
Capital Expenditures during the year ended December 31, 2023 |  | $ | 1,096,819 |  |  | $ | 795,694 |  |  | $ | — |  |  | $ | 1,892,513 |

X
- Definition Tabular disclosure of Total Assets, Depreciation and Amortization, and Capital Expenditures. + References No definition available. + Details
Name: | iccc_TotalAssetsDepreciationAndAmortizationAndCapitalExpendituresTableTextBlock
Namespace Prefix: | iccc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration